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Abstract
The development of antibodies effective in crossing the blood brain barrier (BBB), capable of accessing the cytosol of
affected cells and with higher affinity for PrP
Sc would be of paramount importance in arresting disease progression in its late
stage and treating individuals with prion diseases. Antibody-based therapy appears to be the most promising approach
following the exciting report from White and colleagues, establishing the ‘‘proof-of-principle’’ for prion-immunotherapy.
After passive transfer, anti-prion antibodies were shown to be very effective in curing peripheral but not central rodent
prion disease, due to the fact that these anti-prion antibodies are relatively large molecules and cannot therefore cross the
BBB. Here, we show that an anti-prion antibody derived from camel immunised with murine scrapie material adsorbed to
immunomagnetic beads is able to prevent infection of susceptible N2a cells and cure chronically scrapie-infected
neuroblastoma cultures. This antibody was also shown to transmigrate across the BBB and cross the plasma membrane of
neurons to target cytosolic PrP
C. In contrast, treatment with a conventional anti-prion antibody derived from mouse
immunised with recombinant PrP protein was unable to prevent recurrence of PrP
Sc replication. Furthermore, our camelid
antibody did not display any neurotoxic effects following treatment of susceptible N2a cells as evidenced by TUNEL
staining. These findings demonstrate the potential use of anti-prion camelid antibodies for the treatment of prion and other
related diseases via non-invasive means.
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Introduction
Prion diseases also known as transmissible spongiform enceph-
alopathies (TSEs) are a group of closely related fatal transmissible
neurodegenerative diseases that affect humans and animals [1].
Prion disorders are associated with conversion of the normal
cellular prion protein (PrP
C) into a disease-associated isoform,
PrP
Sc, that acquires increased b-sheet structure and detergent
insolubility [2]. These diseases are characterised by the deposition
and aggregation of proteins into highly stable, partially proteinase-
resistant plaques and fibrils [3], leading to neuronal cell death and
spongiform change of the brain parenchyma [4].
A number of drugs have been assessed for their efficacy in
inhibiting prion replication, and these included polyanions [5],
Iododoxorubicin, tetracycline [6], Congo red [7], polyene
antibiotics [8], and quinacrine [9]. With the exception of an
amphotericine analogue that had some effect on disease
progression [10], these drugs have been shown to be ineffective
in interacting with PrP
Sc in vivo. Moreover, their capacity to
transmigrate across the BBB has not been established.
Following successful treatment of scrapie-susceptible neuroblas-
toma (N2a) cells [11,12,13] and scrapie-infected mice [14],
immune-based therapy has become the most promising therapeu-
tic approach for the treatment of prion diseases [15]. After the
landmark report from White and colleagues [14], showing for the
first time efficacy of anti-prion antibodies in treating animal prion-
disease, other researchers have demonstrated the effectiveness of
antibody-mediated therapy in delaying the onset of disease in vivo
[16,17,18,19,20]. The antibody-mediated therapy approach was
first investigated in scrapie susceptible neuroblastoma cells (N2a)
[12,13], then in transgenic mice with an anti-PrP antibody m-chain
[21]. This was followed by vaccinating scrapie-infected mice with
rPrP [22], PrP peptides [23], and mucosal vaccination using live
attenuated strain of Salmonella typhimurium expressing the
mouse PrP gene [24,25]. Crucially and for the first time, we have
previously shown that passive transfer of anti-PrP monoclonal
antibodies following inoculation of mice with scrapie-infected
material via the intraperitoneal route led to inhibition of prion
replication in vivo and animals survived throughout their life-span
and remained free of detectable prion infection [14]. When the
passive antibody transfer was started after onset of clinical signs of
disease, all animals succumbed to prion diseases and were not
rescued, indicating the inefficiency of these antibodies to
transmigrate across the BBB.
We have previously raised a camelid anti-prion antibody,
known as PrioV3, capable of crossing the BBB in vitro and in vivo
via receptor-mediated transport (M. Tayebi & J. Greenwood,
unpublished data; M. Tayebi et al, presented at the Neuroprion
conference, Madrid, September 2008). PrioV3 displayed binding
specificity for both PrP
C and PrP
Sc and was believed to bind PrP
C
in the cytosol of neurons (Tayebi et al, submitted); In marked
contrast, conventional anti-prion antibodies produced in mouse
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9804against similar target antigen were unable to enter the neuronal
plasma membrane and instead decorated the cell membrane by
staining surface PrP
C (Tayebi et al, submitted).
In this report, we show that PrioV3 anti-prion antibody was
effective in crossing BBB, reduce peripheral prion replication in
vivo and cured chronically scrapie-infected N2a cells and was also
able to abolish prion replication. Finally, we also demonstrate here
that PrioV3 antibody failed to trigger neurotoxic effects as
previously shown with conventional anti-prion antibodies raised
in mouse ([26], M. Tayebi and M. David, submitted).
The camelid anti-prion antibodies could potentially form an
important tool for the neutralisation/clearance of prions in the
cytosol of affected neurons and could be applied for the treatment
of prion and other related protein-misfolding diseases.
Results
PrioV3 anti-prion antibody binds to prion proteins and
peptide
In order to confirm specificity to the prion protein and to
determine its binding motif, PrioV3 anti-prion antibody was
pepscanned (Figure 1A). 20-mer peptide sequences overlapping by
10 amino acids and spanning the 91–230 region of the truncated
prion protein were used to epitope-map the PrioV3 antibody and
was shown to bind to a linear motif on the C-terminal region of the
protein, a sequence that lies between 171 and 190 (Figure 1A).
This region was previously shown to bind to the so-called YYR
motif used by Paramithiotis and colleagues to generate their PrP
Sc-
specific mAbs [27].
Figure 1. PrioV3 binds to both native and denatured prion proteins. (A) PrioV3 antibody was screened with 20-mer amino acid sequences
spanning the 91–230 region of the prion protein and was shown to bind a region between 170 and 19. ICSM18 that binds to a region between 141
and 160 was used as positive control and normal camel serum (NCS) was used as negative control. Goat anti-llama IgG-HRP was used as secondary
detection antibody. Anti-PrP responses were measured in peptide ELISA. Error bars represent the mean antibody level derived from n=8 wells. (B)
PrioV3 antibody bound to native PrP
C inside the cytoplasm of N2a cells (orange arrow), in contrast with ICSM35 that strictly stained cell membrane-
bound PrP
C (blue arrow). Florescence microscopy was performed and images from each source [FITC (450–490 nm), Texas red (510–560 nm) and
DAPI (330–380 nm)] were collected. As control, N2a cells were stained with the secondary anti-llama IgG (green) and anti-mouse IgG antibody (red),
omitting the primary antibodies. Scale bar=25 mm (C) PrP wild type, knock-out and RML-infected brain homogenate were digested with PK and
tested for reactivity PrioV3. PrioV3 strongly bound both PrP
C and PrP
Sc in brain homogenates (pre- and post-PK). For comparison, ICSM35, raised in
mouse (positive), was incubated with brain homogenates prepared from RML-infected and normal brain tissue with and with no PK digestion.
doi:10.1371/journal.pone.0009804.g001
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C was widely expressed on the
surface of N2a cells when probed with anti-prion mAbs raised
against recombinant prion protein [11,28]. Immunofluorescence
analysis of PrioV3 antibody displayed strong binding to cellular
prion protein expressed on the cell plasma membrane, suggesting
its high affinity for PrP
C (Figure 1B). Furthermore, co-localisation
studies have shown that binding with PrioV3 was also recognised
in the cell cytoplasm by immunofluroscence following staining of
intact N2a cells (non-fixed and non-permebealised), unlike
ICSM35-stain that was strictly restricted to the plasma membrane
(Figure 1B). Therefore, PrioV3 binds both surface and cytosolic
PrP
C and recognizes residues 171 and 190 on the C-terminal
region of the truncated PrP
27–30.
To assess the ability of PrioV3 antibody to recognise PrP
Sc,
scrapie-infected (RML) or Prn-p
2/2 (KO) brain homogenate was
treated with PK (QIAGEN) (Figure 1C). Western blot studies
displayed similar binding pattern between PrioV3 and ICSM35;
with several PrP
C bands from normal mice comprising one band at
27 kDa, two 29–32 kDa and 33–35 kDa, and one at 21–22 kDa.
FollowingPKdigestion, PrP
C was completely removed, whereasthe
33–35 kDa form of PrP
Sc was shortened to 27–30 kDa, probably as
a result of degradation of the amino-terminal segment of residues
23–90 analogous to hamster PrP
Sc [29]. PrioV3 antibody did not
react with Prn-p
2/2 brain homogenates. Therefore, PrioV3 was
shown to binds both PrP
C and PrP
Sc whether the protein is in native
conformation or denatured.
PrioV3 antibody is capable of crossing the BBB in vitro
and in vivo
Transport of PrioV3 and ICSM35 antibodies across the blood-
brain barrier was assessed using GPNT rat [30] and HCMEC/D3
human [31] endothelial cells. PrioV3 was shown to cross both BBB
cell lines efficiently as measured by ELISA (Figure 2A). In contrast,
CD71 antibody, Dextran and ICSM35 antibody were unable to
enter the BBB cell lines (Figure 2A). Furthermore, immunohisto-
chemistry and immunofluorescence stain of the brain parenchyma
of rats following intra-venous injection revealed that PrioV3
antibody was widely distributed, in contrast, ICSM35 did not
Figure 2. Assessment of PrioV transmigration across the BBB in vitro and in vivo. (A) BBB migration of PrioV3 antibody was assessed using
GPNT rat and D3 human BBB models. PrioV was shown to cross both BBB cell lines efficiently as measured by ELISA, in contrast with CD71 antibody,
Dextran and ICSM35 (con-IgG) that did not cross the BBB; (B) Immunohistochemistry and immunofluorescence stain of PrioV3 (green) in the brain
parenchyma following intra-venous injection. PrioV3 antibody was injected i.v. to rats and brain sections were taken 4 h later to assess antibody
migration across the BBB in vivo (white arrows). Co-injection with a conventional anti-prion IgG (red) displayed its inability to cross the BBB and
staining remained in the kidney (yellow arrow). Scale bar=5 mm.
doi:10.1371/journal.pone.0009804.g002
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and liver of these rats (Figure 2B).
PrioV3 antibody raised against PrP-Dynabeads inhibits
accumulation of PrP
Sc in ScN2a Cells
We first assessed the efficiency of PrioV3, an anti-prion mAb
antibody raised in camel against PrP-Dynabeads, as an inhibitor of
prion replication in ScN2a cells.
ScN2a cells were cultured in triplicates and treated for 24 hours
or 4 days at 37uC (5% CO2) with PrioV3 antibody. For the 4 day
experiment, treatment was renewed daily in order to maintain
levels of antibody above PrP
C levels, since PrP
C has a rapid
turnover rate (half-time synthesis 0.1 hour vs. half-time degrada-
tion 5 hours) [32]. Normal camel serum (NCS) and no treatment
were used as controls. The cells were then lysed and subsequently
treated with PK prior to analysis of PrP
Sc levels by Sandwich
ELISA and Western blot.
For comparison, ScN2a cells were also treated with 1 or 25 mg
ICSM35, an anti-prion mAb antibody raised against human
recombinant b-PrP (Figure 3). ICSM35 binds residues 91 and 110
on the N-terminal region of the truncated PrP
27–30 and was shown
to be useful in delaying disease onset albeit leading to incomplete
inhibition of PrP
Sc replication in the spleen of scrapie-infected
mice [14,33]. ICSM35 was also previously shown to disturb
cholesterol homeostasis and alter cell signaling (M. Tayebi and M.
David, submitted). An isotype matched control for ICSM35,
BRIC126 was also used and untreated cells were included in the
experiment (Figure 3).
As expected, ICSM35 led to a significant dose-dependent
reduction in PrP
Sc accumulation after 24 hour treatment
(Figure 3). When compared with PrioV3 antibody, ICSM35 was
less potent in inhibiting PrP
Sc replication in ScN2a cells (Figure 3).
ScN2a cells were treated with 1 mgo r2 5mg PrioV3 antibody.
Here, as little as 1 mg/ml of PrioV antibody abrogated PrP
Sc
replication as demonstrated by Sandwich ELISA [(P,0.001),
(Figure 3)]. Although 25 mg/ml of PrioV3 antibody led to a
significant decrease of PrP
Sc as assessed by Sandwich ELISA,
levels did not differ significantly from the 1 mg/ml of PrioV3
antibody treatment, suggesting the high potency of PrioV3
antibody in inhibiting PrP
Sc replication [(P,0.001), (Figure 3)].
We have previously shown that treatment of ovine PrP-
inducible scrapie-infected Rov cells with a panel of the ICSM
mAbs raised against both recombinant a-PrP and b-PrP led to
significant reduction of PrP
Sc accumulation. It was determined
that ICSM35 was the most effective in inhibiting PrP
Sc replication
(x 100 to 1500) following treatment of Rov cells over a period 6
weeks [11]. This also suggests that PrioV3 antibody is a more
potent inhibitor since it was shown to abrogate PrP
Sc replication
after 24 hours only. In disagreement with previous work [11],
PrioV3 antibody did alter PrP
C expression, independent of the
dose or treatment length (Figure 3 and data not shown), indicating
that the antibody has a direct neutralizing effect on PrP
C as well as
PrP
Sc. Of note, mAbs with higher affinity for PrP
C were shown to
be more effective in reducing PrP
Sc replication in a dose
dependent manner [12,13,14].
ScN2a cells were also treated with 25 mg PrioV3 or ICSM35
over a period of 4 days (Figure 4) with daily treatment renewal in
tissue culture medium. NCS and BRIC126 treatment were used as
controls. Following treatment, cells were lysed and then PK
treated as described above. Levels of PrP
Sc were then analysed in
the cell lysates by Sandwich ELISA and Western blotting. Both
PrioV3 antibody and ICSM35 completely abrogated PrP
Sc
replication as shown by Western blot. NCS and BRIC126 had
no effect on PrP
Sc levels (Figure 4).
It has previously been reported that treatment for three [13] or
seven [12] days with anti-PrP
C antibodies abolished PrP
Sc
replication as demonstrated by undetectable levels in Western
blot, in agreement with the present findings.
Figure 3. PrioV3 and ICSM35 antibodies inhibit accumulation of PrP
Sc in ScN2a cells. ScN2a cells were incubated for 24 hours at 37uC (5%
CO2) with 1 or 25 mg PrioV3 and ICSM35. 25 mg NCS (Normal camel serum), and BRIC126-treated as well as untreated cells were also included. The
cells were then lysed and subsequently treated with PK prior to analysis of PrP
Sc levels by Sandwich ELISA in triplicates. Both concentrations of PrioV3
used to treat ScN2a cells show a significant reduction in prion replication (P,0.001) when compared with the NCS control and the untreated cells.
PrioV3 has also led to decreased levels of normal prion protein. ICSM35 led to a significant (P,0.001) reduction in prion replication compared to
BRIC126-treated or untreated cells. Representative of three experiments.
doi:10.1371/journal.pone.0009804.g003
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inhibit prion replication in vivo. Here, mice were inoculated with
RML scrapie brain homogenate and treated weekly with 2 mg of
PrioV3 or isotype control antibody CD71 (IgG) from day 10 post
inoculation (p.i.). Western blot analysis of PrP
Sc at 60 days p.i.
showed a marked inhibition of PrP
Sc accumulation in the spleen
(Figure 5 and data not shown). This pilot study confirms the
inhibitory effects of PrioV3 on PrP
Sc inhibition in vivo and
experiments are currently underway to assess the effects of PrioV3
on clinical disease in mice.
Recurrence of PrP
Sc replication in ICSM35- but not
PrioV3-treated cells
We have also assessed whether PrP
Sc accumulation recurs after
treatment was ceased in PrioV3- and ICSM35-treated ScN2a
cells.
ScN2a cells were treated over a period of 4 days with daily
treatment renewal of antibody in tissue culture medium with 25 mg
of PrioV3 or NCS (Figure 6A) and ICSM35 or BRIC126
(Figure 6B). Untreated cells were also included in the experiment.
Subsequently, cells were treated with antibody-free tissue culture
medium for another 3 days and levels of PrP
Sc were assessed by
Western blot following PK digestion of cell lysates.
Cell lysates assayed 3 days after removal of PrioV3 antibody
failed to display detectable levels of PrP
Sc as demonstrated by
Western blot (Figure 6A) in contrast to ICSM35-treated cells that
displayed high expression levels of PrP
Sc (Figure 6B). Both
untreated as well as cells treated with isotype-matched BRIC126
antibody showed high levels of PrP
Sc replication. Furthermore, 3
days after treatment was discontinued, cell lysates and superna-
tants were screened for the presence of PrioV3 or ICSM35 by
ELISA. Both PrioV3 and ICSM35 were not detected indicating
that PrioV3 inhibitory effect was not the result of residual antibody
in the cells but to its potent effect on PrP
Sc (data not shown).
Taken together, these results suggest that only PrioV3 antibody led
to permanent depletion of PrP
Sc in chronically infected N2a cells.
ICSM35 but not PrioV3 antibody leads to neurotoxicity
PrP
C appears to play a crucial role in the process leading to
neuronal death [34] as neurotoxic effects associated with prion
diseases are not triggered in the absence of PrP
C expression
[35,36]. Furthermore, a role in signal transduction for PrP
C was
Figure 4. Long term treatment with PrioV3 or ICSM35 anti-prion antibodies abrogate PrP
Sc accumulation in ScN2a cells. ScN2a cells
were incubated for 4 days at 37uC (5% CO2) with 25 mg ICSM35 or of PrioV3 and daily treatment renewal in tissue culture medium. BRIC126- and NCS-
treated (Normal camel serum) were also included. The cells were then lysed and subsequently treated with PK prior to analysis of PrP
Sc levels by
Western blot. Both PrioV3 and ICSM35 abrogated PrP
Sc replication when compared with the BRIC- and NCS-treated cells. Representative of three
experiments.
doi:10.1371/journal.pone.0009804.g004
Figure 5. PrioV3 antibody inhibits PrP
Sc replication in spleens of antibody-treated mice. Weekly passive transfer of 2 mg PrioV3 antibody
for 60 days induced substantial reduction in splenic PrP
Sc levels when treatment was started at day 10 p.i. CD71-treated as well as untreated mice did
not inhibit splenic prion replication and this reduction was not observed.
doi:10.1371/journal.pone.0009804.g005
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C-dependent
Fyn activation [37] and modulation of calcium-dependent protein
kinase C in mice [38]. Following a recent report by Solforosi and
colleagues showing that cross-linking PrP
C with specific anti-prion
antibodies leads to neuronal apoptosis in vivo [26], we have shown
that ICSM35 antibody treatment of neurons alters cell membrane
fluidity and leads to disruption of signalling proteins that reside in
membrane domains (M. Tayebi and M. David, submitted).
To determine whether cross-linking PrP
C to PrioV3 antibody
could produce neurotoxic effects in vitro, DNA fragmentation was
evaluated in N2a cells following treatment with varying concen-
trations (0, 5 and 25 mg) of endotoxin-free PrioV3 or ICSM35
antibody.
This study showed that ICSM35 caused DNA fragmentation as
shown by TUNEL stain in a dose-dependent manner (Figure 7C &
D). In contrast, PrioV3 antibody failed to trigger any neurotoxic
effect as demonstrated by TUNEL staining by immunofluorescence,
even at the highest concentration (Figure 7E & F). Interestingly, only
antibodies that recognize epitopes within the 91 to 110 regionof PrP
are capable of triggering neurotoxic-associated effects following
cross-linking with PrP
C ([26], [M. Tayebi and M. David,
submitted]). While PrioV3 antibody, that binds to a PrP sequence
between 171 and 190, failed to elicit neurotoxic effects.
Discussion
The conversion of normal prion protein (PrP
C) into disease-
associated PrP
Sc is a central event underlying the mechanisms of
neuronal degeneration in prion diseases. Therefore, targeting both
normal and disease-associated isoforms should form the basis for
the development of effective therapeutic strategies for prion
disorders.
Given that human prion diseases are normally diagnosed after
onset of disease, it is crucial to develop compounds that can
effectively arrest/reverse the disease process even after symptoms
have began. Although, antibody-mediated therapy was shown to
be effective for the treatment of rodent prion disease, intraperi-
toneal passive transfer of anti-PrP mAb did not have a protective
effect following CNS invasion/inoculation of prions [14]. Due to
their relatively large molecular mass, these anti-PrP mAb were
unable to transfer into the CNS across the blood-brain barrier
when administered peripherally.
Camelids generate functional antibodies consisting of only two
heavy chains in comparison with the conventional four-chain
antibodies; and differs from the corresponding regions of
conventional antibodies in that they lack the CH1 domain [39].
Since they are devoid of the light chains, the antigen binding site of
camelid antibodies is limited to a single domain. Camelid
antibodies are tools of increasing interest for CNS therapy
[40,41,42] and biophysical studies have revealed that they possess
a number of unique features compared to those of conventional
antibody fragments, notably smaller size (,14 kDa), greater
solubility and higher stability [40]. In that context, we have
produced a camelid anti-prion antibody fragment, known as
PrioV3, able to transmigrate across the BBB and cross the plasma
membrane of neurons to target cytosolic PrP
C (Tayebi et al
submitted).
In this report, we show that PrioV3 binds to both PrP
C and
PrP
Sc and effectively abrogates prion replication in ScN2a cells,
but it is unclear whether its inhibitory effects are due to recognition
of normal and/or disease-associated isoform of prion protein.
However, it was reported that PrP
C cleavage with phosphatidy-
linositol-specific phospholipase C from the cell surface [13] or
stabilization with specific antibodies of PrP
C alone is sufficient to
inhibit PrP
Sc replication [12,13,14]. Furthermore, Perrier and
colleagues [43] demonstrated that anti-PrP antibodies block PrP
Sc
replication in prion-infected cell cultures by accelerating PrP
C
degradation.
We also show in this report that immunidetection of PrP
Sc from
spleens of mice at 60 days p.i. revealed that treatment with PrioV3,
but not with CD71 antibody markedly inhibited PrP
Sc accumu-
lation when passive transfer started at day 10. This is in agreement
with previous reports [14] demonstrating efficacy of a mouse mAb
raised against alpha recombinant protein (i.e. ICSM18) in
abrogating splenic prion replication following ip inoculation with
RML. Of importance, mice treated with ICSM18 survived
indefinitely [14].
Previous reports have shown that binding of anti-PrP antibodies
to helix 1 region of PrP
C, which is believed to play a crucial role in
the conversion process [44,45] inhibits PrP
Sc accumulation in
ScN2a cells by preventing interaction of PrP
C with PrP
Sc [12,13].
However, these antibodies were less efficient in clearing prion
infection when used for the treatment of Rov cells [11,12]. Thus,
antibodies that bind to a-helix domain are able to abrogate prion
Figure 6. PrioV3 but not ICSM35 anti-prion antibody permanently inhibits accumulation of PrP
Sc in ScN2a cells following cessation
of antibody treatment. ScN2a cells were incubated for 4 days at 37uC (5% CO2) with 25 mg of (A) PrioV3 and (B) ICSM35* and daily treatment
renewal in tissue culture medium. NCS- (Normal camel serum) and BRIC126-treated cells were also included. The cells were then further grown for
another three with antibody-free tissue culture medium. The cells were then lysed and subsequently treated with PK prior to analysis of PrP
Sc levels
by Western blot. PrioV3 treatment led to permanent inhibition of PrP
Sc replication but ICSM35-treated cultures displayed de-novo replication of PrP
Sc;
both the BRIC- and NCS-treated cells showed high levels of PrP
Sc. Representative of three experiments.
doi:10.1371/journal.pone.0009804.g006
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whereas, their ability to cure an ovine epithelial cell line (Rov cells)
infected with prion was shown to be poor [11]. More importantly,
ICSM35, which displays higher affinity for PrP
Sc, also failed to
completely rid scrapie-infected mice [14] and ScN2a cells (this
study) of PrP
Sc, but led to efficient prion inhibition in Rov cells
[11]. Therefore, anti-PrP mAbs should be chosen on the basis that
they selectively target species-specific prion strains.
The PrioV3 antibody was able to completely abrogate PrP
Sc
replication in prion-permissive neuronal cultures even after
treatment was ceased. This is in agreement with Enari and
colleagues that demonstrated that ScN2a exposure to an anti-PrP
C
mAb not only prevented infection but also cured chronically
scrapie-infected cells after treatment was ceased [13]. In contrast,
ICSM35 failed to prevent recurrence of the PrP
Sc replication in
ICSM35-treated neuronal cultures [11]. Bioassay of infectivity
from these lysates is in progress.
Mechanisms underlying differential outcome of PrP
Sc inhibition
following treatment with anti-PrP antibodies remain unknown and
clearly need to be further investigated, since antibodies thought to
be effective in eradicating prion infection could in fact only
suppress disease transiently. It could be speculated that variable
levels of PrP
C expression in different cell lines/types would lead to
diverse inhibitory effects [11,13]. Further, differences in the
binding affinities of antibodies used to inhibit PrP
Sc replication
could also help to explain the difference in treatment outcome,
given that PrP
C is ubiquitously expressed [46] and, in some cases,
higher concentrations would be needed to achieve complete
abrogation of prion replication. Binding specific motifs on the
prion protein could also explain this dichotomy; for instance,
Figure 7. ICSM35 but not PrioV3 anti-prion antibody leads to neurotoxicity N2a cells following antibody treatment. N2a cells were
assessed for neurotoxic effects by immunofluorescence imaging following treatment with PrioV3 or ICSM35. (A) Proprietary positive TUNEL stain and
(B) antibody-free tissue culture medium were used as controls. Following treatment with 5 and 25 mg PrioV3 or ICSM35, TUNEL staining was only
observed when cells were treated with ICSM35 (C & D). PrioV3 did not elicit DNA fragmentation and toxic effects were not observed (E & F). Cell nuclei
were also stained with DAPI. Scale bar=5 mm. Representative of three experiments.
doi:10.1371/journal.pone.0009804.g007
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region of the prion protein led to cell membrane disruption in vitro
(M. Tayebi and M. David, submitted) and neurotoxic effects in vivo
[26]. Whether the binding property of these antibodies to specific
sequences is enough to explain these outcomes remain to be
resolved. PrioV3 antibody could potentially turn out to be a more
useful therapeutic tool for eradicating prion infection since it binds
a more C-terminal region of the protein and targets both isoforms
of the prion protein. In this case, PrioV3 antibody would be able
to block PrP
C incorporation into propagating infectious agents and
at the same time neutralize the infectious template, PrP
Sc.
PrioV3 antibody displayed extensive and diffuse binding of
PrP
C in the cytoplasm of cells without permebealization. PrioV3
ability to enter and target the cytosol of neurons remains
unknown, but we speculate that this is due to the size of the
antibody fragment (,14 kDa) as ICSM35 (,175 kDa) was unable
to enter the cell.
Although many studies addressed the question of whether
antibodies could inhibit PrP
Sc replication in vitro and in vivo,
previous reports have demonstrated that cross-linking anti-prion
antibodies with PrP
C leads to deleterious effects on neurons in vivo
[26] and in vitro (M. Tayebi and M. David, submitted). Solforosi
and co-workers used antibodies that specifically bind to epitopes
within the N-terminal (95–105) and the C-terminal (133–157)
regions of the prion protein. Interestingly, antibodies directed
against codons within the 95–105 but not to the 133–157 the
region led to apoptosis [26], while antibodies that target a more C-
terminal region failed to display neurotoxic effects in prion
infected mice and cells [18,26]. Similarly, the current study
showed that PrioV3 antibody which also binds to the C-terminal
(71–190) region of the prion protein did not trigger neuronal
apoptosis.
The mechanism(s) of prion-mediated neuronal degeneration are
not fully understood but it is believed that this is caused by
increased PrP
Sc neurotoxicity, so-called ‘‘gain of function hypoth-
esis’’ as prn-p
2/2 mice displayed no obvious phenotype [47], or by
loss of PrP
C function. It is likely that the apoptotic phenomenon
observed after cross-linking of PrP
C with ‘toxic’ antibodies mimics
the prion-mediated degenerative process and leads to antibody-
mediated loss of function. The favourable efficiency and toxicity
property observed for PrioV3 together with its ability to cross the
BBB and to enter the plasma membrane of affected neurons makes
it an attractive weapon in the fight against prion and other related
diseases.
Materials and Methods
Production of anti-prion camelid antibodies
All procedures involving animals were carried out under a
project and personal licence authority issued in accordance with
The Animals (Scientific Procedures) Act 1986 and approval by the
Royal Veterinary College Institutional Ethics Committee.
Preparation of Dynabead-adsorbed antigen for immunisation
was performed as described [48]. Briefly, RML-infected brains
from terminally ill scrapie-infected wild type FVB/N mice were
used for the preparation of Dynabead-adsorbed antigen [48].
Sheep anti-mouse IgG-coupled immunomagnetic Dynabead
particles (Invitrogen) were resuspended with an excess of IgG
mAb anti-prion antibody (1–2 mg antibody/10
7 Dynabeads).
The Dynabeads/mAb complex was incubated overnight at 4uC
then washed several times with PBS to remove excess mAb.
100 ml of 1% scrapie infected brain homogenate was incubated
with 1610
6 mAb-coated Dynabeads for at least 2 hours at
room temperature. The final complex, known as PrP-Dyna-
beads, was then rinsed and resuspended in PBS before
immunisation.
Three adult male camels received six subcutaneous injections at
weekly intervals of PrP-Dynabeads. For the first injection the
antigen was mixed with an equal volume of Freund’s Complete
Adjuvant (FCA), and all subsequent boosts were with Freund’s
Incomplete Adjuvant (FIA). Forty-five days after the first injection,
50 ml of anticoagulated blood was collected to evaluate the
immune response and used to isolate lymphocytes for mRNA
extraction [49]. mRNA extraction was followed by cDNA
preparation and the final PCR fragments were ligated into a
phagemid vector as reported [49]. Ligated material was trans-
formed in Escherichia coli cells and specific antibodies against prion
proteins (PrioVs) were enriched by three consecutive rounds of in
vitro selection. PrioV3 antibody was used in the current study.
ICSM anti-PrP mAbs (D-Gen) were produced as described [33].
ICSM 18, an IgG1, binds PrP
C strongly in its native state but
weakly to native PrP
Sc, and to both isoforms in Western blots. Its
epitope lies between codons 144–156. ICSM 35, an IgG2b binds
both PrP
C and PrP
Sc from all species tested, whether the protein is
in a native conformation or denatured. Its epitope lies between
residues 91–110.
Peptides and pepscan ELISA
20-mer peptides spanning the truncated prion protein and
overlapping by 10 amino acids were made by automated solid
phase step-wise synthesis using the Fmoc N terminal protection
chemistry as described [48]. Briefly, peptides were cleaved from
the solid phase and fully side-chain deprotected using trifluor-
oacetic acid with water and tri-isopropylsilane as scavengers.
Cleaved peptides were precipitated and washed in ice-cold methyl
tertiary butyl ether, dried, dissolved in suitable aqueous solvents
and analysed by reverse phase HPLC and MALDI-TOF mass
spectrometry.
High binding, 96 well plates (Greiner) were coated with 50 ml/
well of a 10 mg/ml peptide solution in coating buffer (35 mM
NaHCO3, 15 mM Na2CO3, pH 9.6). The plates were incubated
for 1 hour at 37uC then washed 3 times with PBS-0.05% Tween
20, and then blocked with SuperBlock (SB; Pierce) for 1 hour at
room temperature. After decanting the SB, 50 ml of PrioV3
antibody diluted in PBS-0.05% tween 20 was added and
incubated for 1 hour at 37uC. The plates were then washed 3
times with PBS-0.05% tween and a 1/1000 dilution of
horseradish-peroxidase (HRP) conjugated goat anti-llama IgG
(Bethyl Laboratories) was added for 25 min at 37uC and the plates
were again washed 4 times with PBS-0.05% tween. Finally, the
plates were developed with OPD buffer (Sigma) until optimum
development occurred, when the reaction was stopped with 3 M
sulphuric acid prior to spectrophotometric reading at 490 nm.
Tranmigration studies across the blood-brain barrier
Rat and human brain microvascular endothelial cell lines
[30,31] were used in vitro to assess trancytosis of both PrioV3 and
ICSM35 antibodies. The brain microvascular endothelial cell lines
were seeded on collagen-coated Falcon tissue culture inserts in the
top chamber (1 mm pore size). The bottom chamber of the insert
assembly contained appropriate medium (with no cells). The
ability of PrioV3 antibody to transmigrate across the in vitro BBB
model was assessed by adding 10 or 25 mg of the antibody into the
upper compartment and determining the concentration in 200 ml
aliquots from the bottom chamber at specified times using by
ELISA.
In order to investigate whether PrioV3 retains the ability to
cross the BBB in vivo, rats were injected in the tail vein or via
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hours after injection, the animals were anesthetized. brain, liver
and kidney were dissected and processed for histology.
Cell culture
Mouse N2a neuroblastoma cultures were plated at 2–4610
6 in
Opti-MEM medium [0.5% (W/V) glucose supplemented with 5%
fetal bovine serum (FBS), 50 U/ml penicillin, 50 mg/ml strepto-
mycin and 200 mM L-glutamine]. Cultures were maintained at
37uCi n5 %C O 2 with a change of medium every 48–72 hours.
Immunofluorescence staining and imaging
For subsequent immunofluorescence staining with anti-prion
antibodies (PrioV3 and ICSM35 antibodies), N2a cells were first
seeded on glass coverslips in 35-mm dishes and grown to 50%
confluence at 37uC in a humidified atmosphere of 5% CO2/95%
on air. Coverslips were then rinsed three times in TBS (1 M tris-
HCl, 1.5 M NaCl, pH 7.5) and 100 ml of blocking buffer [(1% (v/
v) FBS, 1% BSA (w/v) in TBS] was added. The coverslips were
incubated with 100 ml PrioV3 and/or ICSM35 for 1 hour at RT
followed by the secondary antisera diluted in TBS [(anti-llama IgG
FITC-conjugate, Bethyl; anti-mouse IgG Texas red-conjugate,
Sigma)] for 1 hour at RT. After the final wash in TBS, the
coverslips were mounted in fluorescence anti-fade solution
(Invitrogen) and sealed with clear nail polish to prevent
dehydration. 4, 6-dimidino-2-phenylindole (DAPI) (Sigma) was
diluted to 2 mg/ml in fluorescence anti-fade solution for nuclear
staining and added to coverslips.
Florescence microscopy was performed with a Leica DM4000B
microscope. Images from each source [FITC (450–490 nm),
Texas red (510–560 nm) and DAPI (330–380 nm)] were collected
by a high resolution DC500 colour camera attached. All images
are saved digitally using Leica’s IM500 Image Manager Database
software from the same field-of-view. Images were merged using
Photoshop 6.0 (Adobe).
Treatment of ScN2a with antibody
For subsequent treatment with anti-prion antibodies, ScN2a
cells were plated using 6 or 24 well plates (Falcon) at 1610
4 cells/
well and grown at 37uCi n5 %C O 2 for a minimum of 24 hours.
Appropriate antibody concentrations were added to 1610
4
ScN2a cells, and left to incubate for 24 hours or 4 days at 37uC
(5% CO2). For the 4 day treatment, ScN2a cultures, antibody-
containing tissue culture medium was added daily. The cells were
then removed from the wells and centrifuged at 800 rpm for 5
minutes. The pellet was lysed with 50 ml lysis buffer followed by
1 mg/ml Proteinase K (PK; Roche) treatment for 25 minutes at
37uC. AEBSF protease inhibitor (Roche) was then added to inhibit
PK activity. Cells were then stored at 220uC until further use.
Levels of PrP
Sc in the culture were then analysed by Sandwich
ELISA and Western blot.
To assess recurrence of PrP
Sc replication following removal of
antibody, 1610
4 ScN2a cells were incubated for 4 days with daily
replacement of antibody-containing tissue culture medium as
described above. Following treatment stoppage, ScN2a cultures
were continuously fed for another 3 days with tissue culture
medium without antibody supplement. Cells were then treated
with PK and analysed for the presence of PrP
Sc by Sandwich
ELISA and Western blot.
Protein extraction from cells
ScN2a cells were washed twice in PBS and homogenised in an
extraction buffer containing 10 mM Tris-HCl, 100 mM NaCl,
10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate
and 0.2% sodium dodecyl sulphate (SDS) at 10
6 cells/ml. AEBSF
protease inhibitor (Roche) was added to some cell extracts.
Membranes were prepared by repeated passage with a Wheaton
homogeniser; nuclei and large fragments were removed.
Sandwich ELISA analysis
Medium binding, 96 well ELISA plates (Greiner) were coated
with 50 mlo fa1mg/ml ICSM18 antibody solution in coating
buffer. The plates were incubated for 1 hour at 37uC then washed
3 times with PBS-0.05% tween, and then blocked with RF10 for
1 hour at room temperature. After decanting the RF10, cell lysates
were diluted in PBS-0.05% tween with protease inhibitors (Roche
Biochemicals) were added and incubated for 1 hour at 37uC. The
plates were then washed 3 times with PBS-0.05% tween and a
1 mg/ml of biotinylated ICSM35 was added for 1 hour at 37uC
and the plates were again washed 3 times with PBS-0.05% tween
before a 1/1000 dilution of horseradish-peroxidase (HRP)
conjugated anti-mouse IgG (Sigma) was added for 25 min at
37uC and the plates were again washed 4 times with PBS-0.05%
tween. Finally the plates were developed with OPD buffer until
optimum development occurred and the reaction was stopped
with 3 M sulphuric acid prior to spectrophotometric reading at
490 nm.
Western blot analysis
Samples to be electrophoresed were diluted 1:1 in 40 ml
sample buffer and boiled for 5 min in eppendorf tubes. The
samples were spun for 5 seconds at 14.000 rpm in a microfuge
before being loaded on the gel. The gels were electrophoresed
at a constant voltage of 200 V for 1 hour. Following
electrophoresis, gels were blotted onto PVDF (Invitrogen) at
18 V for 45 min. Following blotting, the membranes were
rinsed in PBS-tween (0.05%) before being transferred to
blocking solution for 60 min at room temperature. The
membranes were again rinsed in PBS-tween (0.05%) to remove
all traces of blocking solution. PrioV3, ICSM35 or ICSM18
antibody was added and incubated for 1 hour at room
temperature. Following 4 washes of 5 min each, the membranes
were then incubated in anti-mouse or anti-llama IgG HRP-
conjugated antibody diluted at 1 in 20,000. The membranes
were washed as above and developed using the Hybond-
chemiluminescence (ECL) system (GE Healthcare), according to
the manufacturer’s instructions. Signal development times
ranged from 1 second to 30 min.
Assessment of neurotoxicity by TUNEL staining
Apoptosis was assessed by TUNEL staining using an apoptosis
KIT according to manufacturing instructions (Calbiochem). DNA
fragmentation was evaluated in ScN2a cells following treatment
with varying concentrations of PRIOV3 and ICSM35. Briefly,
cells were fixed with 50 ml of LEUCOPERM Reagent A (Serotec)
for 10 minutes at room temperature. Cells were then washed with
PBS and 100 ml of 5 x TdT Equilibrium Buffer was added (1:5
TdT: H2O) and left to incubate for 10 min. After removing the
solution, 30 ml of 1:20 Fluorescein Labelling Reaction Mix: TdT
Enzyme was added and incubated for 1 hour at 37uC. The slides
were then washed 4 times with PBS for 15 minutes prior to adding
15 ml of DAPI nuclear stain (1:600 DAPI: PBS). The cells were
viewed with a LEICA DM4000B fluorescence microscope
equipped with a Bio-Rad MRC1024 laser confocal scanning
system and a LEICA DC500 camera. Images were layer-
combined with Adobe Photoshop.
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Sc levels following treatment of
mice with PrioV3
Five FVB/N mice were inoculated via the intraperitoneal (i.p.)
route with Rocky Mountain Laboratory (RML) scrapie brain
homogenate derived from terminally scrapie-sick mice and treated
with PrioV3 or isotype control antibody CD71 by a weekly i.p.
injection (2 mg per injection) from 10 day post inoculation (p.i.).
Statistical analysis
One-way ANOVA with Dunnett’s post test was performed
using GraphPad Prism version 5.00 for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com for
statistical analysis.
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